Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature

Bentea, Georgiana Pintea; Sculier, Claudine; Grigoriu, Bogdan; Meert, Anne-Pascale; Durieux, Valérie; Berghmans, Thierry; Sculier, Jean-Paul

doi:10.1016/j.lungcan.2017.01.017

Cited by 16 publications

(12 citation statements)

References 186 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most frequent manifestations found were rheumatoid arthritis (5.9%), psoriasis (2.8%), polymyalgia rheumatica (1.8%), Addison disease (1%), systemic lupus erythematosus (SLE-−0.9%), ulcerative colitis (0.8%), giant cell arteritis (0.8%), sicca syndrome (0.6%), regional enteritis (0.5%), and Meniere disease (0.5%). However, these autoimmune manifestations can be very broad as it has been recently reviewed for lung cancer in a series of articles curated by Jean Paul Scuiler (1,(8)(9)(10)(11).…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders

et al. 2020

Self Cite

View full text Add to dashboard Cite

Immunotherapy is an important armamentarium for cancer treatment nowadays. Apart from their significant effectiveness in controlling disease they also generate potential severe immune related adverse effects. Preexistence of immune related conditions may eventually predispose to the development of more severe complication and extreme caution have been taken in treating these patients. We performed a literature review searching for case reports and case series in order to offer evidence-based data for clinical management of these patients. Preexisting serological-only immune abnormalities or presence of a predisposing genetic background does not seem to confer significant risk but existing data is scarce. Most patients with preexistent autoimmune diseases can probably treated with checkpoint inhibitors as they seem to have at least the same response rate as the general cancer population. Under treatment, a significant part of them (at least 30%) can experience a flare of their baseline disease which can sometime be severe. Life-threatening cases seems rare and disease flare can be generally managed with steroids. The volume of available data is more important for rheumatologic diseases than for inflammatory bowel diseases were more caution should be observed. However, it has to be kept in mind that new immune related adverse effects (IrAE) are seen with a similar frequency as the flare of the baseline disease. Both flare-up's and newly developed IrAE are generally manageable with a careful clinical follow-up and prompt therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is unlikely the patient's positive P/Q type Calcium channel blocker antibody was directly related to his neurologic symptoms. This antibody has been historically associated with Lambert-Eaton syndrome with or without opsoclonus-myoclonus, cerebellar degeneration and less commonly encephalomyeloneuropathic syndromes [7,8]. It is more likely this finding was indicative of disordered immune regulation.…”

Section: Discussionmentioning

confidence: 99%

A Case of Paraneoplastic Myoclonus Attributed to Non-Small Cell Lung Cancer

Nichols

Lee

Chung

2020

Tremor and Other Hyperkinetic Movements

View full text Add to dashboard Cite

“…Another intriguing feature of our study was the low mortality rate (6/27; 22%). Also, although the death rate of patients with intracellular antibodies is known to be quite high (20), only 4 out of 16 patients with well-characterized paraneoplastic antibodies (Hu, Yo, Ri, Ma2, CV2 and amphiphysin) had died during their follow-up. A potential reason for the low cancer and mortality rates in our study might be the relatively short follow-up duration.…”

Section: Discussionmentioning

confidence: 99%